Key Takeaways
- Fontem US, LLC and OM Investment, LLC filed suit in the Northern District of Texas on March 17, 2026.
- The defendants include FDA, HHS, and two officials sued in their official capacities.
- The complaint says the Zone nicotine pouch PMTAs were originally submitted in May 2022, and FDA did not issue a refusal-to-file decision until December 16, 2025.
- FDA issued a “Corrected” Refuse-to-File Letter on March 12, 2026, maintaining its position.
- The plaintiffs ask the court to declare the decision unlawful, vacate it, and issue temporary and permanent injunctive relief blocking enforcement.
2Firsts, March 19, 2026
According to the court filing, Fontem US, LLC and OM Investment, LLC filed suit on March 17, 2026 in the U.S. District Court for the Northern District of Texas, Fort Worth Division, against the Food and Drug Administration, the Department of Health and Human Services, and related officials, seeking declaratory and injunctive relief over FDA’s refusal-to-file decision affecting certain Zone nicotine pouch PMTAs.
The complaint says Fontem is a nicotine pouch manufacturer and OM Investment, LLC, doing business as Andy Food Store, sells the products in Fort Worth, Texas. The plaintiffs state that the PMTAs were submitted in May 2022 and that, under the Tobacco Control Act, FDA was required to issue an order either allowing or denying marketing within 180 days.
The filing says FDA did not act within that statutory period and instead issued a Refuse-to-File Letter on December 16, 2025, followed by a “Corrected” Refuse-to-File Letter on March 12, 2026, which maintained the agency’s decision.
According to the complaint, FDA said the applications lacked information concerning ingredient data for other products used in bridging analyses and therefore refused to file the PMTAs. The plaintiffs argue that the Tobacco Control Act does not provide a third option to refuse to file and that FDA must either grant or deny an application based on the required public-health review.
The complaint also argues that FDA violated its own regulations, changed its review approach without fair notice, and ignored information already in its possession. It further alleges that the official who signed the decision was not properly appointed under the Appointments Clause, making the action unconstitutional.
The plaintiffs ask the court to declare the decision unlawful, set it aside, and issue an administrative stay, temporary restraining order, preliminary injunction, and permanent injunction preventing FDA from taking enforcement action based on the decision.
Fontem US LLC is a wholly-owned subsidiary of the international tobacco giant Imperial Brands, and is primarily responsible for the operations, research and development, and regulatory compliance of its e-cigarette and Nicotine Pouch brand,in the US market.
Image source: Law360
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
